SCHEMBL770562

SCHEMBL770562

CCC(O)(NC(=O)CCCC(=O)N1CCCC2CCCCC21)c1cccc(O)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.38
RAB9A P51151 3/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HSD11B1 P28845 3/20 0.36
ACE P12821 3/20 0.35
ACE2 Q9BYF1 3/20 0.35
HSD17B1 P14061 1/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
DPP4 P27487 2/20 0.35
DPP8 Q6V1X1 1/20 0.35
PDE3B Q13370 1/20 0.34
PDE3A Q14432 1/20 0.34
DRD2 P14416 1/20 0.34
DRD4 P21917 1/20 0.34
POLB P06746 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
HPGD P15428 1/20 0.34
F2 P00734 1/20 0.34
ALDH1A1 P00352 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL771812 0.89 NPC1 (0.46) NPC1RAB9ASMN1; SMN2HSD11B1ACE
SCHEMBL772163 0.89 DPP4 (0.42) NPC1RAB9ASMN1; SMN2HSD11B1ACE
SCHEMBL770561 0.74 ALDH1A1 (0.41) NPC1RAB9ASMN1; SMN2HSD11B1ACE
SCHEMBL772459 0.73 NPC1 (0.46) NPC1RAB9ASMN1; SMN2HSD11B1HSD17B1
SCHEMBL772521 0.72 HRH3 (0.54) NPC1RAB9AMEN1KMT2ADPP4
SCHEMBL770615 0.71 DRD2 (0.49) NPC1RAB9ASMN1; SMN2HSD11B1MEN1
SCHEMBL17690709 0.70 TRPV1 (0.46) NPC1RAB9ASMN1; SMN2HSD11B1DPP4
SCHEMBL770458 0.70 OPRD1 (0.40) NPC1RAB9ASMN1; SMN2HSD11B1MEN1
SCHEMBL770091 0.69 OPRD1 (0.45) ACEACE2DPP4NPSR1
SCHEMBL770291 0.69 GAA (0.56) NPC1RAB9ASMN1; SMN2HSD11B1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822452-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2014-09-02 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-8524894-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2013-09-03 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 NPC1 97/4885RAB9A 2187/4885SMN1; SMN2 3653/4885
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 NPC1 104/4885RAB9A 2217/4885SMN1; SMN2 3637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.